Gianluca Masi

20.3k total citations · 2 hit papers
257 papers, 7.6k citations indexed

About

Gianluca Masi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Gianluca Masi has authored 257 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Oncology, 106 papers in Pulmonary and Respiratory Medicine and 96 papers in Hepatology. Recurrent topics in Gianluca Masi's work include Colorectal Cancer Treatments and Studies (174 papers), Hepatocellular Carcinoma Treatment and Prognosis (96 papers) and Cancer Treatment and Pharmacology (84 papers). Gianluca Masi is often cited by papers focused on Colorectal Cancer Treatments and Studies (174 papers), Hepatocellular Carcinoma Treatment and Prognosis (96 papers) and Cancer Treatment and Pharmacology (84 papers). Gianluca Masi collaborates with scholars based in Italy, United States and Germany. Gianluca Masi's co-authors include Alfredo Falcone, Fotios Loupakis, Chiara Cremolini, Lisa Salvatore, Giacomo Allegrini, Giuseppe Tonini, I. Brunetti, Enrico Cortesi, E. Pfanner and Daniele Santini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gianluca Masi

240 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

2007 872 citations Alfredo Falcone, Sergio Ricci et al. Journal of Clinical Oncology profile →
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

2014 720 citations Fotios Loupakis, Chiara Cremolini et al. profile →

Peers

Countries citing papers authored by Gianluca Masi

Since Specialization

Citations

This map shows the geographic impact of Gianluca Masi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gianluca Masi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gianluca Masi more than expected).

Fields of papers citing papers by Gianluca Masi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gianluca Masi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gianluca Masi. The network helps show where Gianluca Masi may publish in the future.

Co-authorship network of co-authors of Gianluca Masi

This figure shows the co-authorship network connecting the top 25 collaborators of Gianluca Masi. A scholar is included among the top collaborators of Gianluca Masi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gianluca Masi. Gianluca Masi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 2025 ·European Journal of Cancer ·Roberto Moretto, Daniele Rossini, (unknown), Carlotta Antoniotti, Rossana Intini, Veronica Conca, (unknown), (unknown), Lisa Salvatore, Marco Maria Germani, Francesca Bergamo, Alessandro Passardi, (unknown), Emiliano Tamburini, (unknown), (unknown), Gianluca Masi, Filippo Pietrantonio, Sara Lonardi, Chiara Cremolini	0
2	FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials 2025 ·European Journal of Cancer ·Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, Hans‐Joachim Schmoll, Sara Lonardi, (unknown), Beatrice Borelli, Samanta Cupini, Alexander Stein, Roberto Moretto, Francesca Bergamo, Monica Ronzoni, Marco Maria Germani, Alberto Zaniboni, (unknown), (unknown), Elena Ongaro, Gianluca Masi, Chiara Cremolini	0
3	Concordance of PD-L1 combined positive score (CPS) analysis between primary gastric cancer and matched peritoneal metastasis. 2024 ·Journal of Clinical Oncology ·Valentina Massa, Francesca Salani, (unknown), (unknown), Caterina Vivaldi, (unknown), Clara Ugolini, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Vincenzo Nardini, Gianluca Masi, Lorenzo Fornaro	0
4	Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial. 2024 ·Journal of Clinical Oncology ·Veronica Conca, (unknown), Paola Vignali, Daniele Rossini, Marco Maria Germani, Francesca Bergamo, Filippo Pietrantonio, Beatrice Borelli, Federica Marmorino, Mirella Giordano, Giovanni Randon, (unknown), (unknown), (unknown), Angela Buonadonna, Alberto Zaniboni, Lorenzo Antonuzzo, Gianluca Masi, Clara Ugolini, Chiara Cremolini	0
5	International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). 2024 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Tae‐You Kim, Jean‐Frédéric Blanc, Olivier Rosmorduc, Thomas Decaens, Philippe Mathurin, Philippe Merle, Farshid Dayyani, Gianluca Masi, Tiziana Pressiani, Peter R. Galle, Ken Hatogai, Yuko Ishii, Henrik Seidel, U. Mueller, Stacey Kalambakas, Mohamed Bouattour	13
6	Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study. 2024 ·Journal of Clinical Oncology ·(unknown), Veronica Conca, Roberto Moretto, Carlotta Antoniotti, Margherita Ambrosini, Sabina Murgioni, (unknown), Alessandra Russo, Francesca Bergamo, Giovanni Randon, (unknown), (unknown), Federica Marmorino, Beatrice Borelli, Marco Maria Germani, (unknown), (unknown), (unknown), Gianluca Masi, Chiara Cremolini	1
7	KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration 2024 ·JCO Precision Oncology ·Roberto Moretto, (unknown), Sabina Murgioni, (unknown), (unknown), Marco Maria Germani, Maria Alessandra Calegari, (unknown), Rossana Intini, (unknown), (unknown), (unknown), Alessandro Passardi, Emiliano Tamburini, (unknown), Lisa Salvatore, Filippo Pietrantonio, Sara Lonardi, Gianluca Masi, Chiara Cremolini	1
8	Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging 2023 ·Cancers ·Piero Boraschi, Roberto Moretto, Francescamaria Donati, Beatrice Borelli, (unknown), (unknown), Alessandra Boccaccino, (unknown), (unknown), S Signori, Gianluca Masi, Chiara Cremolini, Lucio Urbani	3
9	Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 2023 ·European Journal of Cancer ·Daniele Rossini, Alessandra Boccaccino, (unknown), Carlotta Antoniotti, (unknown), (unknown), Federica Marmorino, Roberto Moretto, Gianluca Masi, Chiara Cremolini	18
10	Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 2023 ·Cancers ·Giacomo Aringhieri, (unknown), Silvia Catanese, Caterina Vivaldi, Francesca Salani, Saverio Vitali, (unknown), Enrico Vasile, (unknown), Lorenzo Fornaro, (unknown), (unknown), Carla Cappelli, Dania Cioni, Gianluca Masi, Emanuele Neri	3
11	Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 2023 ·Cancers ·V. Fanotto, Daniele Rossini, Mariaelena Casagrande, Francesca Bergamo, A. Spagnoletti, Daniele Santini, Carlotta Antoniotti, Samanta Cupini, Francesca Daniel, (unknown), (unknown), Alberto Zaniboni, Beatrice Borelli, (unknown), Veronica Conca, Alessandro Passardi, Emiliano Tamburini, Gianluca Masi, Nicoletta Pella, Chiara Cremolini	1
12	Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective Analysis 2022 ·Vaccines ·(unknown), (unknown), (unknown), Andrea Sbrana, (unknown), (unknown), (unknown), (unknown), Marco Ferrari, Giulia Massaro, (unknown), (unknown), Luca Galli, Riccardo Morganti, Andrea Antonuzzo, Chiara Cremolini, Gianluca Masi	1
13	Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy? 2022 ·Updates in Surgery ·Matteo Palmeri, Andrea Peri, (unknown), Niccolò Furbetta, (unknown), Gregorio Di Franco, Anna Pagani, (unknown), (unknown), Desirée Gianardi, Simone Guadagni, Matteo Bianchini, Annalisa Comandatore, Gianluca Masi, Chiara Cremolini, Beatrice Borelli, Luca Emanuele Pollina, Giulio Di Candio, Andrea Pietrabissa, Luca Morelli	1
14	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 2021 ·Clinical Colorectal Cancer ·Roberto Moretto, Daniele Rossini, Iolanda Capone, Alessandra Boccaccino, Federica Perrone, Elena Tamborini, Gianluca Masi, Carlotta Antoniotti, Federica Marmorino, Veronica Conca, Beatrice Borelli, Angelo Martignetti, Irene Pecora, Francesca Simionato, Samanta Cupini, Margherita Ambrosini, Paolo Manca, Filippo Pietrantonio, Alfredo Falcone, Chiara Cremolini	12
15	Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings 2020 ·La radiologia medica ·Michela Gabelloni, (unknown), Riccardo Morganti, Lorenzo Faggioni, Gianluca Masi, Alfredo Falcone, Emanuele Neri	37
16	HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer 2020 ·The Oncologist ·Caterina Vivaldi, Lorenzo Fornaro, Clara Ugolini, Cristina Niccoli, Gianna Musettini, Irene Pecora, Andrea Cacciato Insilla, Francesca Salani, G. Pasquini, Silvia Catanese, Monica Lencioni, Gianluca Masi, Daniela Campani, (unknown), Alfredo Falcone, Enrico Vasile	39
17	Minor-but-Complex Liver Resection 2015 ·Medicine ·Lucio Urbani, Gianluca Masi, Marco Puccini, P. Colombatto, Caterina Vivaldi, Riccardo Balestri, (unknown), (unknown), Francesco Forfori, (unknown), Chiara Leoni, A. Paolicchi, Piero Boraschi, (unknown), Carlo Tascini, Maura Castagna, P Buccianti	14
18	Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis 2014 ·Annals of Oncology ·Chiara Cremolini, Fotios Loupakis, Daniele Rossini, Gianluca Masi, Lisa Salvatore, C. Barbara, I. Brunetti, Carlotta Antoniotti, Cristina Granetto, Enrico Cortesi, S. Chiara, S. Vitello, Sara Lonardi, L. Ciuffreda, Giovanni Tomasello, Monica Ronzoni, Angela Buonadonna, (unknown), Luca Boni, Alfredo Falcone	2
19	Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. 2012 ·Annals of Oncology ·Lisa Salvatore, Fotios Loupakis, Chiara Cremolini, Marta Schirripa, Gianluca Masi, Carlotta Antoniotti, Lorenzo Fornaro, Elisa Sensi, Cristiana Lupi, Francesca Bergamo, Sara Lonardi, (unknown), Gabriella Fontanini, Alfredo Falcone	4
20	Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases 2009 ·Annals of Surgery ·Gianluca Masi, Fotios Loupakis, Luca Emanuele Pollina, Enrico Vasile, Samanta Cupini, Sergio Ricci, I. Brunetti, Roberta Ferraldeschi, Giuseppe Naso, Franco Filipponi, Andrea Pietrabissa, Orlando Goletti, Giacomo Giulio Baldi, Lorenzo Fornaro, M. Andreuccetti, Alfredo Falcone	165

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact